BYDUREON 2 mg POWDER AND DILUENT FOR PROLONGED-RELEASE INJECTABLE SUSPENSION IN A PRE-FILLED PEN

2. What you need to know before you use Bydureon

Do not use Bydureon:

• If you are allergic to exenatide or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, pharmacist, or diabetes nurse before you start using Bydureon about the following:

• If you use this medicine in combination with a sulfonylurea, as low blood sugar (hypoglycemia) may occur. Check your blood sugar levels regularly. Ask your doctor, pharmacist, or diabetes nurse if you are not sure if any of your other medicines contain a sulfonylurea.
• If you have type 1 diabetes or diabetic ketoacidosis, as this medicine should not be used.
• How to inject this medicine. It must be injected into the skin and not into a vein or muscle.
• The use of this medicine is not recommended if you have severe problems with emptying your stomach (including gastroparesis) or with food digestion. The active substance in this medicine delays stomach emptying, so food passes more slowly through your stomach.
• If you have ever had pancreatitis (inflammation of the pancreas) (see section 4).
• Tell your doctor if you lose weight too quickly (more than 1.5 kg per week), as this can cause problems such as gallstones.
• If you have severe kidney disease or are on dialysis, as the use of this medicine is not recommended.

Bydureon is not an insulin, so it should not be used as a substitute for insulin.

Children and adolescents

Bydureon can be used in adolescents and children aged 10 years and older. There is no data available on the use of this medicine in children under 10 years of age.

Using Bydureon with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines, especially:

• other medicines used to treat type 2 diabetes, such as medicines that work like Bydureon (e.g., liraglutide or other medicines that contain exenatide), as it is not recommended to use these medicines with Bydureon.
• medicines used to thin the blood (anticoagulants), e.g., warfarin, as you may need closer monitoring of changes in your INR (a measure of blood clotting) during the start of therapy with this medicine.
• a medicine that contains a sulfonylurea, as low blood sugar (hypoglycemia) may occur when combined with Bydureon.
• if you are receiving insulin, your doctor will tell you how to reduce your insulin dose and recommend that you check your blood sugar level more often to avoid high blood sugar (hyperglycemia) and diabetic ketoacidosis (a complication of diabetes that occurs when the body cannot break down glucose because there is not enough insulin).

Pregnancy and breastfeeding

It is not known if this medicine can harm your unborn baby, so you should not use it during pregnancy or for at least 3 months before a planned pregnancy.

It is not known if exenatide passes into breast milk. You should not use this medicine during breastfeeding.

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, ask your doctor or pharmacist for advice before using this medicine.

You should use contraception if you could become pregnant during treatment with this medicine.

Driving and using machines

If you use this medicine in combination with a sulfonylurea, low blood sugar (hypoglycemia) may occur. Hypoglycemia can reduce your ability to concentrate. Please be aware of this possible problem in situations where you could put yourself or others at risk (e.g., driving a car or using machines).

Important information about some of the ingredients of Bydureon

This medicine contains less than 1 mmol (23 mg) of sodium per dose, which is essentially "sodium-free".

3. How to use Bydureon

Follow the instructions for administration of this medicine exactly as told by your doctor, pharmacist, or diabetes nurse. If you are not sure, talk to your doctor, pharmacist, or diabetes nurse again.

You should inject this medicine once a week, at any time of day, with or without food.

You should inject this medicine into the skin (subcutaneous injection) in the area around your stomach (abdomen), in the upper part of your leg (thigh), or in the upper back part of your arm. Do not inject into a vein or muscle.

You can use the same area each week. Make sure to choose a different injection site within that area.

Never mix insulin and Bydureon in the same injection. If you need to administer both at the same time, use two separate injections. You can inject both in the same area (e.g., in the area around your stomach) but do not inject one next to the other.

Check your blood sugar levels regularly, especially if you are using a sulfonylurea.

To inject Bydureon, follow the "Instructions for the User" included in the pack.

Your doctor or diabetes nurse should teach you how to inject this medicine before you use it for the first time.

Take a pen out of the refrigerator and let it sit at room temperature for at least 15 minutes. Before you start, check that the liquid in the pen is clear and free of particles. After you mix the liquid with the powder, use the suspension only if the mixture is between white and off-white and cloudy. If you see dry powder clumps on the sides of the pen, the medicine is NOT mixed well. Tap the pen firmly again until it is well mixed.

You should inject this medicine immediately after mixing the powder and solvent.

Use a new pen for each injection. You should dispose of the pen safely, with the needle still attached, after use, as your doctor or diabetes nurse has told you.

If you use more Bydureon than you should

If you use more of this medicine than you should, talk to your doctor before taking any more. You may need medical treatment. Too much of this medicine can cause nausea, vomiting, dizziness, or low blood sugar symptoms (see section 4).

If you forget to use Bydureon

You might find it helpful to set a specific day to take your Bydureon injection each week.

If you forget a dose and there are 3 days or more until your next scheduled dose, take the missed dose as soon as possible. For your next injection, you can go back to your usual day.

If you forget a dose and there are only 1 or 2 days until your next scheduled dose, skip the missed dose and take your next dose on the scheduled day. You can also change the day you take your injection, as long as the last dose was given 3 or more days before.

Do not take two doses of Bydureon if there are less than 3 days between them.

If you are not sure if you have taken your full dose of Bydureon:

If you are not sure if you took your full dose, do not take another dose of this medicine. Just take your next dose at the scheduled time.

If you stop using Bydureon

If you think you need to stop using this medicine, talk to your doctor first. If you stop using this medicine, it may affect your blood sugar levels.

If you have any other questions about using this medicine, ask your doctor, pharmacist, or diabetes nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Severe allergic reactions(anaphylaxis) have been reported rarely (may affect up to 1 in 1,000 people).

See your doctor immediately if you experience symptoms such as

• Swelling of the face, tongue, or throat (angioedema)
• Hypersensitivity (rash, itching, and rapid swelling of the tissues of the neck, face, mouth, or throat)
• Difficulty swallowing
• Hives and difficulty breathing

Cases of pancreatitis(inflammation of the pancreas) have been reported uncommonly (may affect up to 1 in 100 people) in patients treated with this medicine. Pancreatitis can be a serious medical condition that can be life-threatening.

• Tell your doctor if you have had pancreatitis, gallstones, alcoholism, or very high triglycerides. These medical conditions may increase the risk of pancreatitis or make it worse, whether or not you are taking this medicine.

• Stop taking this medicine and contact your doctor immediatelyif you have severe and persistent stomach pain, with or without vomiting, as you may have pancreatitis.

Very common side effects(may affect more than 1 in 10 people)

• nausea (nausea is more common when starting treatment with this medicine but decreases over time in most patients)
• diarrhea
• low blood sugar (hypoglycemia) when used with a sulfonylurea

When this medicine is used with a sulfonylurea, episodes of low blood sugar (hypoglycemia, usually mild to moderate) may occur. It may be necessary to reduce the dose of your sulfonylurea medicine while using this medicine. The signs and symptoms of low blood sugar can include headache, drowsiness, weakness, dizziness, confusion, irritability, hunger, rapid heartbeat, sweating, and a feeling of nervousness. Your doctor should tell you how to treat low blood sugar.

Common side effects(may affect up to 1 in 10 people)

• low blood sugar (hypoglycemia) when used with insulin
• dizziness
• headache
• vomiting
• lack of energy and strength
• fatigue
• constipation
• stomach pain
• swelling
• indigestion
• flatulence (gas)
• heartburn
• decreased appetite

This medicine may reduce your appetite, the amount of food you eat, and your weight. Tell your doctor if you lose weight too quickly (more than 1.5 kg per week), as this can cause problems such as gallstones.

• injection site reactions

If you experience an injection site reaction (redness, rash, or itching), you can talk to your doctor about something to help relieve any signs or symptoms. After injection, you may see or feel a small lump under your skin; this should disappear after 4 to 8 weeks. You should not need to stop your treatment.

Uncommon side effects

• decreased kidney function
• dehydration, sometimes with decreased kidney function
• intestinal obstruction (blockage in the intestine)
• belching
• unusual taste in the mouth
• increased sweating
• hair loss
• sleepiness
• delayed gastric emptying
• inflamed gallbladder
• gallstones

Rare side effects

• nervousness

Not known(frequency cannot be estimated from the available data)

In addition, the following other adverse reactionshave been reported:

• bleeding or bruising more easily than normal due to a low level of platelets in the blood.
• changes in INR (a measure of blood clotting) have been reported when used with warfarin.
• skin reactions at the injection site after injection of exenatide. These include: a pocket of pus (abscess) and an area of swollen, red, hot, and painful skin (cellulitis).

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or diabetes nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Bydureon

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of the month shown.

Store in a refrigerator (between 2°C and 8°C). Do not freeze.

The pen can be stored for up to 4 weeks below 30°C before use.

Store in the original package to protect from light.

Discard any Bydureon pen that has been frozen.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container contents and additional information

Composition of Bydureon

• The active ingredient is exenatide. Each preloaded pen contains 2 mg of exenatide. After suspension, a dose of 2 mg/0.65 ml is obtained.
• The other components are:
• In the powder: poly (D, L-lactide-co-glycolide) and sucrose.
• In the solvent: sodium carmellose; sodium chloride; polysorbate 20; sodium dihydrogen phosphate monohydrate; disodium phosphate heptahydrate, water for injectable preparations, and sodium hydroxide (for pH adjustment).

Appearance of the product and container contents

This medication is supplied as a powder and solvent (liquid) for injectable suspension in a preloaded pen. The powder (2 mg), contained in one of the chambers, is white to off-white in color, and the solvent (0.65 ml), contained in the other chamber, is a clear, colorless to pale yellow, to pale brown solution. Each single-dose preloaded pen is supplied with a measured dose needle. Each container also includes a spare needle.

This medication is available in a package of 4 single-dose preloaded pens and a multiple package containing 12 (3 packages of 4) single-dose preloaded pens. Only certain package sizes may be marketed.

Marketing authorization holder:

AstraZeneca AB

SE-151 85 Södertälje

Sweden

Manufacturer:

AstraZeneca AB

Gärtunavägen

SE-151 85 Södertälje

Sweden

AstraZeneca UK Limited

Silk Road Business Park,

Macclesfield, Cheshire, SK10 2NA

United Kingdom

Swords Laboratories T/A Lawrence Laboratories

Unit 12 Distribution Centre, Shannon Industrial Estate, Shannon, Co. Clare

Ireland

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Date of the last revision of this prospectus:

Other sources of information

Detailed information about this medication is available on the European Medicines Agency website http://www.ema.europa.eu/.